Suchergebnisse - "Zhou, Jianying"

PubPharm (61)

1

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study

enthalten in: Cancer communications (London, England) | 2024

von Zheng, J. | Wang, T. | Yang, Y. | +41

2

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6) : single-arm, open-label, multicentre, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2024

von Wang, M. | Fan, Y. | Sun, M. | +37

3

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Drilon, A. | Camidge, D. | Lin, J. | +131

4

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Solomon, B. | Loong, H. | +122

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126

5

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264

6

A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease

enthalten in: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences | 2023

von Sun, W. | Zheng, J. | Zhou, J. | +1

7

Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study : a case report

enthalten in: Anti-cancer drugs | 2023

von Wu, L. | Cheng, Y. | Huang, D. | +7

8

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer : a randomized, multicenter, open-label, phase III trial

enthalten in: Signal transduction and targeted therapy | 2023

von Yang, Y. | Min, J. | Yang, N. | +17

9

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

10

Interim survival analysis of the randomized phase III GEMSTONE-302 trial : sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

enthalten in: Nature cancer | 2023

von Zhou, C. | Wang, Z. | Sun, M. | +31

ErratumIn: Nat Cancer. 2024 Jan 5;:. - PMID 38182915

1
2
3
4
5
6
7
Nächster »
[7]